Overview

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

Status:
Completed

Trial end date:
1997-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.

Phase:

Phase 3

Details

Lead Sponsor:

Alza Corporation, DE, USA

Treatments:

Mandelic Acids
Oxybutynin